Conquering Diseases

Study Of An Experimental Treatment Using Hyperimmune Intravenous Immunoglobulin For Covid-19 In Hospitalized Adults

Description

Seeking men and women aged 18 and older who have been hospitalized for COVID-19 for a study of an experimental treatment using Hyperimmune Intravenous Immunoglobulin containing antibodies for COVID-19.

Overview

We are studying an experimental treatment using hyperimmune Intravenous Immunoglobulin that contains antibodies against the virus that causes COVID-19 to see if it helps hospitalized adults recovery more quickly. Half of the study participants will receive the investigational drug and half will receive a placebo that looks like the investigational drug but doesn't contain any medicine. All participants will also receive treatment with the drug Remdesivir.

What we're hoping for

We hope to evaluate whether the experimental treatment using hyperimmune intravenous immunoglobulin containing antibodies for COVID-19 helps people hospitalized with COVID-19 recover more quickly.

Additional Information

ClinicalTrials.gov Identifier: NCT04546581

 Principal Investigator

Jonathan M. Gerber, MD

University of Massachusetts Medical School

 Study Contact

UMass COVID  Plasma Team

UMassCOVIDplasma@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989